NPCE — NeuroPace Inc
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1528287 ·
Last close
$16.68
Market Cap
$568.68M
52W High
$19.60
52W Low
$12.47
ADV30
202,680
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 22,068,000 | 18,048,000 | -5,568,000 | -6,689,000 | 98,898,000 | 14,779,000 | 84,444,000 |
| Dec 2025 | 26,588,000 | 20,578,000 | -1,767,000 | -2,729,000 | 105,565,000 | 21,692,000 | 86,534,000 |
| Sep 2025 | 27,354,000 | 21,168,000 | -2,600,000 | -3,496,000 | 107,255,000 | 20,648,000 | 88,737,000 |
| Jun 2025 | 23,520,000 | 18,132,000 | -6,824,000 | -8,651,000 | 106,114,000 | 22,857,000 | 86,676,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-11,006,000
Investing CF
$-332,000
Financing CF
$19,600,000
CapEx
$-332,000
Dividends Paid
—
Buybacks
$-49,546,000
EPS Diluted TTM
$-0.66
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-552,415,000
Inventory
$16,896,000
Receivables
$14,681,000
ST Investments
$39,366,000
EBIT TTM
$-14,008,000
Pretax Income TTM
$-21,465,000
Interest Exp TTM
$7,457,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$99,530,000
EBITDA
$-16,510,000
Free Cash Flow
$-2,739,000
Enterprise Value
$585,164,672
Total Cash
$53,981,000
Total Debt
$70,462,000
Shares Out
34,093,745
Trailing EPS
$-0.65
Book Value
$0.57
ROE
-111.4%
ROA
-10.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 99,986,000 | -16,338,000 | -21,465,000 | 105,565,000 | 86,534,000 | — | -11,006,000 |
| Dec 2024 | 79,906,000 | -21,671,000 | -27,141,000 | 94,647,000 | 86,634,000 | — | -17,949,000 |
| Dec 2023 | 65,421,000 | -27,174,000 | -32,956,000 | 107,651,000 | 86,997,000 | — | -19,701,000 |
| Dec 2022 | 45,520,000 | -40,794,000 | -47,082,000 | 114,106,000 | 79,329,000 | — | -36,869,000 |
TTM Snapshot
Revenues TTM
$58,983,000
NetIncome TTM
$-32,577,000
OpCashFlow TTM
$0
Assets (Latest)
$94,647,000
Forward EPS
$-0.30
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TCMD | TACTILE SYSTEMS TECHNOLOGY INC | $565.26M | $25.06 | — |
| CERS | CERUS CORP | $547.01M | $2.73 | — |
| MDXG | MIMEDX GROUP, INC. | $546.63M | $3.67 | — |
| BVS | Bioventus Inc. | $611.09M | $9.02 | — |
| BBNX | Beta Bionics, Inc. | $522.26M | $11.72 | — |
News headlines (Yahoo Finance, 1h cache)
NeuroPace (NPCE) Q1 2026 Earnings Transcript
2026-05-14 19:23 · Yahoo
NeuroPace, Inc. (NASDAQ:NPCE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
2026-05-14 18:54 · Yahoo
NeuroPace, Inc. Q1 2026 Earnings Call Summary
2026-05-13 12:30 · Yahoo
NeuroPace Inc (NPCE) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...
2026-05-13 05:02 · Yahoo
NeuroPace Q1 Earnings Call Highlights
2026-05-13 01:09 · Yahoo
NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates
2026-05-12 21:40 · Yahoo
NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
2026-05-12 20:05 · Yahoo
NeuroPace (NPCE) Moves 6.3% Higher: Will This Strength Last?
2026-05-07 13:32 · Yahoo
NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026
2026-04-29 20:05 · Yahoo
NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026
2026-04-27 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.